( OTC Bulletin Board : ILNS ) , a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer 's disease ( " AD " ) , announced today that several of its significant shareholders ( the " Interested Shareholders " ) have agreed in principle to provide interim funding to the Company and assist the Company in its efforts to restructure its balance sheet . � � The Company has initiated discussions with the Interested Shareholders regarding a potential equity financing to fund operations for a longer period than that covered by the interim funding .